-
Jenburkt's Investigational Cancer Drug Fails to Meet Primary Endpoint in Phase 2 Trial
Jenburkt's investigational cancer drug, JTX-2011, has failed to meet its primary endpoint in a Phase 2 trial, the company announced today. The drug was being evaluated in patients with locally advanced or metastatic urothelial cancer who had previously received platinum-based chemotherapy.
-
Jenburkt Raises $100 Million in Series C Funding to Advance Cancer Pipeline
Jenburkt Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel cancer therapies, today announced the closing of a $100 million Series C financing round. The funding will be used to advance the company's pipeline of cancer therapies, including its lead drug candidate, JTX-2011, which is currently in Phase 2 clinical development for the treatment of urothelial cancer.
-
Jenburkt Appoints New Chief Medical Officer
Jenburkt Pharmaceuticals Ltd. today announced the appointment of Dr. John Smith as its new Chief Medical Officer. Dr. Smith has over 20 years of experience in the pharmaceutical industry, including leadership roles at several major pharmaceutical companies. He will be responsible for overseeing the clinical development of Jenburkt's pipeline of cancer therapies.
-
Jenburkt Pharmaceuticals Announces Positive Phase 2a Data for JBK-122 in Moderate-to-Severe Atopic Dermatitis
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JBUR) today announced positive topline results from its Phase 2a clinical trial evaluating the efficacy and safety of JBK-122, a novel, oral, small molecule JAK1 inhibitor, in patients with moderate-to-severe atopic dermatitis (AD). The trial met its primary endpoint, demonstrating a statistically significant improvement in the Eczema Area and Severity Index (EASI) score from baseline to Week 8 compared to placebo.
-
Jenburkt Pharmaceuticals Announces Collaboration with Incyte to Develop and Commercialize Novel JAK Inhibitors for the Treatment of Inflammatory Diseases
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JBUR) and Incyte (NASDAQ: INCY) today announced a collaboration to develop and commercialize novel JAK inhibitors for the treatment of inflammatory diseases. The collaboration will leverage Jenburkt's expertise in JAK biology and Incyte's experience in developing and commercializing JAK inhibitors.
-
Jenburkt Pharmaceuticals Announces FDA Clearance of IND for JBK-122 in Systemic Lupus Erythematosus
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JBUR) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for JBK-122, the Company's novel, oral, small molecule JAK1 inhibitor, for the treatment of systemic lupus erythematosus (SLE).
-
Jenburkt Pharmaceuticals Announces Positive Results from Phase 2b Trial of JBT-101 in Patients with Advanced Solid Tumors
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JNP), a clinical-stage biopharmaceutical company, today announced positive results from its Phase 2b trial of JBT-101, an investigational, orally administered small molecule inhibitor of the MDM2-p53 pathway, in patients with advanced solid tumors.
-
Jenburkt Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JNP), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $10.00 per share.
-
Jenburkt Pharmaceuticals Announces Initiation of Phase 3 Trial of JBT-101 in Patients with Advanced Hepatocellular Carcinoma
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JNP), a clinical-stage biopharmaceutical company, today announced the initiation of its Phase 3 trial of JBT-101, an investigational, orally administered small molecule inhibitor of the MDM2-p53 pathway, in patients with advanced hepatocellular carcinoma (HCC).
-
Jenburkt Pharmaceuticals Announces Positive Results from Phase 2 Trial of JBT-101 in Patients with Advanced Solid Tumors
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR) today announced positive results from a Phase 2 clinical trial of JBT-101, its lead investigational drug candidate, in patients with advanced solid tumors. The trial met its primary endpoint of objective response rate (ORR), with an ORR of 15.0% in the overall population and 20.0% in the subset of patients with microsatellite instability-high (MSI-H) tumors.
-
Jenburkt Pharmaceuticals to Present at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR) today announced that it will present data from its Phase 2 clinical trial of JBT-101, its lead investigational drug candidate, in patients with advanced solid tumors, at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which will be held in Denver, Colorado, from April 15-19, 2023.
-
Jenburkt Pharmaceuticals Announces Initiation of Phase 3 Clinical Trial of JBT-101 in Patients with Advanced Gastric Cancer
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR) today announced the initiation of a Phase 3 clinical trial of JBT-101, its lead investigational drug candidate, in patients with advanced gastric cancer. The trial will evaluate the safety and efficacy of JBT-101 in combination with standard chemotherapy compared to standard chemotherapy alone.
-
Jenburkt Announces Positive Topline Results from Phase 3 Trial of JBT-101 in Patients with Metastatic Triple-Negative Breast Cancer
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for oncology, today announced positive topline results from the Phase 3 JEWEL clinical trial (NCT04256017) of JBT-101, an investigational antibody-drug conjugate (ADC), in patients with metastatic triple-negative breast cancer (TNBC).
-
Jenburkt Reports Fourth Quarter and Full Year 2022 Financial Results
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Jenburkt Presents Updated Data from Phase 2 Trial of JBT-101 in Patients with Advanced Urothelial Carcinoma at the 2023 ASCO Genitourinary Cancers Symposium
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for oncology, today announced the presentation of updated data from the Phase 2 JAVELIN clinical trial (NCT03478086) of JBT-101, an investigational antibody-drug conjugate (ADC), in patients with advanced urothelial carcinoma (UC).
-
Jenburkt Pharmaceuticals Announces Positive Topline Results from Phase 3 Trial of JBT-101 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBRT) today announced positive topline results from the Phase 3 ADAPT trial evaluating the efficacy and safety of JBT-101, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
-
Jenburkt Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBRT) today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT / 4:30 p.m. ET.
-
Jenburkt Pharmaceuticals Announces Pricing of Initial Public Offering
Jenburkt Pharmaceuticals Ltd. (the “Company” or “Jenburkt”) today announced the pricing of its initial public offering of 8,000,000 American Depositary Shares (“ADSs”) at a price to the public of \$16.00 per ADS.
-
Jenburkt Pharmaceuticals Announces Positive Phase 2b Results for Lead Asset JBT-101 in Moderate-to-Severe Atopic Dermatitis
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JBUR) (“Jenburkt” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immune-mediated diseases, today announced positive topline results from the Phase 2b dose-ranging study (JBT-101-006) of JBT-101, the Company’s lead investigational monoclonal antibody (mAb) targeting OX40L, in patients with moderate-to-severe atopic dermatitis (AD).
-
Jenburkt Pharmaceuticals to Present at the 45th Annual J.P. Morgan Healthcare Conference
Jenburkt Pharmaceuticals Ltd. (NASDAQ: JBUR) (“Jenburkt” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immune-mediated diseases, today announced that management will present a company overview at the 45th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 8:00 AM ET.
-
Jenburkt Pharmaceuticals Announces Pricing of Initial Public Offering
Jenburkt Pharmaceuticals Ltd. (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immune-mediated diseases, today announced the pricing of its initial public offering of 6,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, at a public offering price of $17.00 per ADS.
-
Jenburkt Pharmaceuticals Announces Positive Phase 2a Results for JBP485 in Non-Alcoholic Steatohepatitis (NASH)
Jenburkt Pharmaceuticals Ltd. (ASX: JBP) is pleased to announce positive Phase 2a results for its lead drug candidate, JBP485, in non-alcoholic steatohepatitis (NASH).
-
Jenburkt Pharmaceuticals to Present at the International Liver Congress™ 2023
Jenburkt Pharmaceuticals Ltd. (ASX: JBP) is pleased to announce that it will be presenting at the International Liver Congress™ 2023.
-
Jenburkt Pharmaceuticals Appoints Dr. Craig Rayner as Chief Medical Officer
Jenburkt Pharmaceuticals Ltd. (ASX: JBP) is pleased to announce the appointment of Dr. Craig Rayner as Chief Medical Officer.
-
Jenburkt Pharmaceuticals Announces Positive Phase 2a Data for JBT-101 in Patients with Moderate-to-Severe Atopic Dermatitis
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR), a clinical-stage biopharmaceutical company developing novel immunology therapies for treating chronic inflammatory and autoimmune diseases, today announced positive topline results from its Phase 2a clinical trial evaluating the safety and efficacy of JBT-101, its investigational anti-OX40 monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (AD).
-
Jenburkt Pharmaceuticals Presents Positive Preclinical Data for JBT-101 in Systemic Lupus Erythematosus (SLE) at the 2023 American College of Rheumatology (ACR) Convergence Annual Meeting
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR), a clinical-stage biopharmaceutical company developing novel immunology therapies for treating chronic inflammatory and autoimmune diseases, today announced the presentation of positive preclinical data for JBT-101, its investigational anti-OX40 monoclonal antibody, in systemic lupus erythematosus (SLE) at the 2023 American College of Rheumatology (ACR) Convergence Annual Meeting, taking place in Philadelphia, Pennsylvania, from November 10-14.
-
Jenburkt Pharmaceuticals Announces Positive Phase 1 Data for JBT-451, a Novel Anti-CD40 Monoclonal Antibody, in Healthy Volunteers
Jenburkt Pharmaceuticals Ltd. (Nasdaq: JBUR), a clinical-stage biopharmaceutical company developing novel immunology therapies for treating chronic inflammatory and autoimmune diseases, today announced positive topline results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of JBT-451, its investigational anti-CD40 monoclonal antibody, in healthy volunteers.